Robust global biopharmaceutical pipeline offers new hope for patients, says PhRMA

The biopharmaceutical pipeline is innovative and robust, with a high proportion of potential first-in-class medicines and therapies targeting diseases with limited treatment options, according to a new report released last week by the Pharmaceutical Research and Manufacturers of America (PhRMA).

The report, developed by the Analysis Group and supported by PhRMA, reveals that more than 5,000 new medicines are in the pipeline globally. Of these medicines in various phases of clinical development, 70% are potential first-in-class medicines, which could provide exciting new approaches to treating disease for patients.

“Biopharmaceutical companies, working with other partners in the American research ecosystem, have made incredible progress in helping confront some of the most challenging and costly diseases facing patients around the world,” said John Castellani, president and chief executive of PhRMA, adding: “With more than 5,000 medicines in development for patients suffering from a wide range of diseases, there is a palpable excitement around the biopharmaceutical pipeline and the future opportunities for new, cutting-edge medicines to improve patient care and bring value to the entire US health care system.”